1 y, and accuracy and was applied to support a
pharmacokinetic study.
2 tion was supported by the results of a 3-day
pharmacokinetic study.
3 ntered into this phase I dose-escalation and
pharmacokinetic study.
4 ized, one treatment, one period, single dose
pharmacokinetic study.
5 This was an open-label
pharmacokinetic study.
6 in parallel for a 15 time point, preclinical
pharmacokinetic study.
7 el from the NC formulation in an independent
pharmacokinetic study.
8 dice patients and can be used to support its
pharmacokinetic study.
9 eived a single 400-mg dose of vorinostat for
pharmacokinetic studies.
10 er profiled in additional in vivo models and
pharmacokinetic studies.
11 r during dissection and assay in traditional
pharmacokinetic studies.
12 e and reasonable oral bioavailability in dog
pharmacokinetic studies.
13 e for the reduction of the use of animals in
pharmacokinetic studies.
14 applied to the analysis of plasma samples in
pharmacokinetic studies.
15 t advantage in high-throughput screening for
pharmacokinetic studies.
16 ns is important both for epidemiological and
pharmacokinetic studies.
17 xyphenyl)-4H-chromen-4-one) was selected for
pharmacokinetic studies.
18 used to analyze plasma samples from several
pharmacokinetic studies.
19 ine-131 images were quantitated and used for
pharmacokinetic studies.
20 nd in plasma is presented as a first step in
pharmacokinetic studies.
21 g microfluidic devices for advanced cell and
pharmacokinetic studies.
22 , elimination) and PBPK (physiological-based
pharmacokinetic) studies.
23 tro pharmacokinetics experiments and in vivo
pharmacokinetics studies.
24 ategy has potential applications in clinical
pharmacokinetics studies.
25 tro pharmacokinetics experiments and in vivo
pharmacokinetics studies.
26 An oral
pharmacokinetic study (
60 mg/m2) was conducted in infant
27 pounds exhibit poor systemic exposure in rat
pharmacokinetic studies after oral dosing.
28 Ten patients participated in an extensive
pharmacokinetic study after week 50.
29 ons in basic biochemical research as well as
pharmacokinetic studies and biomarker discovery.
30 Pharmacokinetic studies and ERBB-receptor expression and
31 on of atrazine and its metabolites in future
pharmacokinetic studies and for the subsequent developme
32 analyze biological samples from both in vivo
pharmacokinetic studies and in vitro microsomal/S9 stabi
33 We then carried out
pharmacokinetic studies and measured cortical nitric oxi
34 oups are necessary to compare results across
pharmacokinetic studies and to assess potential subgroup
35 Pharmacokinetic studies and UGT1A1 genotyping were perfo
36 to "OROS-methylphenidate") were conducted: a
pharmacokinetic study and a pharmacodynamic study.
37 (Pred) regimen first in a phase I safety and
pharmacokinetic study and then in a phase II assessment
38 combinant monoclonal antibodies in serum for
pharmacokinetics studies and it can also be used where s
39 ike molecule and has a half-life of 1 h in a
pharmacokinetics study and a reasonable oral availabilit
40 Plasma samples were obtained for
pharmacokinetic studies,
and a population approach via n
41 day 14 of each phase, blood was sampled for
pharmacokinetic studies,
and the area under the concentr
42 gh concentrations of exposure in plasma by a
pharmacokinetic study,
and (3) reduce the tumor size of
43 ntology was demonstrated by annotating three
pharmacokinetics studies;
and the utility of the PK-corp
44 Two sequential six-patient
pharmacokinetic studies are described, followed by clini
45 During pediatric drug development, dedicated
pharmacokinetic studies are generally performed in all r
46 examethasone is used widely in oncology, but
pharmacokinetic studies are lacking.
47 Tracer
pharmacokinetic studies are often used in treatment plan
48 s, especially for supporting long-term human
pharmacokinetic studies,
are being raised.
49 Pharmacokinetic studies assessed in vivo differences in
50 During the 8-week study period,
pharmacokinetic studies assessed the bioequivalence of G
51 samples for SRI plasma levels were drawn for
pharmacokinetic studies before surgery and 1, 6, and 12
52 Subjects had
pharmacokinetic studies before transplantation and for u
53 d need to be carried out in parallel so that
pharmacokinetic studies can be undertaken as formulation
54 d rectal mononuclear cells from an intensive
pharmacokinetic study ("
Cell-PrEP" [preexposure prophyla
55 In this
pharmacokinetic study,
CF patients and control subjects
56 In a mouse
pharmacokinetics study,
compound 9t was brain-penetrant
57 prospective, sequence-randomized, replicate
pharmacokinetic study conducted at 5 US academic epileps
58 Ex vivo brain
pharmacokinetic studies confirmed the low in vivo PIB re
59 In the long-term
pharmacokinetic studies,
corneal CsA levels ranged from
60 In a single equivalent-dose
pharmacokinetic study,
DDCs enhanced the drug exposure b
61 Pharmacokinetic studies demonstrate that this compound i
62 Pharmacokinetic studies demonstrated 90% oral bioavailab
63 Detailed
pharmacokinetic studies demonstrated linear kinetics up
64 Pharmacokinetic studies demonstrated that BoNT/A was rap
65 Pharmacokinetic studies demonstrated that BX 471 was ora
66 In vivo
pharmacokinetic studies demonstrated that CD4-BFFI was s
67 Pharmacokinetic studies demonstrated that CRA/IFNalpha c
68 Pharmacokinetic studies demonstrated that irinotecan cle
69 Pharmacokinetic studies demonstrated that the plasma con
70 Efficient and opportunistic
pharmacokinetic study designs, typically using sparse sa
71 in a rat model show no adverse events, and a
pharmacokinetics study documents a peak plasma concentra
72 For the phase 1 (
pharmacokinetic) study,
eligible patients had measurable
73 High throughput in vivo rodent cassette
pharmacokinetic studies enabled rapid validation of in v
74 Pharmacokinetic studies established that 13-d had proper
75 uation of circulating angiogenic factors and
pharmacokinetic studies failed to provide insight into t
76 Pharmacokinetic studies following subcutaneous administr
77 er in the 300-mg arm of the SSAT040 TMC278LA
pharmacokinetic study for rilpivirine (RPV) resistance.
78 Recent
pharmacokinetic studies have demonstrated that proton pu
79 We performed 24-hour intensive
pharmacokinetic studies in 111 women receiving efavirenz
80 Serial CSF samples were obtained for
pharmacokinetic studies in a subset of patients with Omm
81 nalization of drug therapies, as well as for
pharmacokinetic studies in both animals and humans.
82 Preliminary
pharmacokinetic studies in dog demonstrated excellent or
83 Implant A was used in long-term
pharmacokinetic studies in dogs aged more than 1 year.
84 11 studies of descriptive cohorts, and three
pharmacokinetic studies in end-stage renal disease, yiel
85 Pharmacokinetic studies in free-swimming adults revealed
86 Pharmacokinetic studies in human FcRn transgenic mice an
87 ternative to labeling with radioisotopes for
pharmacokinetic studies in humans.
88 hat react with reduced BBI are being used in
pharmacokinetic studies in humans.
89 bel for peptide hormones would be useful for
pharmacokinetic studies in infants, children, and pregna
90 ments were analyzed in both transcytosis and
pharmacokinetic studies in mice and in competition bindi
91 In
pharmacokinetic studies in mice and rats, increased plas
92 The system was tested for
pharmacokinetic studies in mice by quantifying myocardia
93 Extensive in vitro screening and in vivo
pharmacokinetic studies in mice helped to identify two l
94 Pharmacokinetic studies in mice revealed that hSGZ exhib
95 In vivo
pharmacokinetic studies in mice show minimal uptake of p
96 In addition, toxicity and
pharmacokinetic studies in mice show significantly impro
97 Pharmacokinetic studies in mice showed a more than 1-log
98 valuate this possibility, we carried out MTX
pharmacokinetic studies in mice that received transplant
99 ons of 4 SHALs were labeled with (111)In for
pharmacokinetic studies in mice with HLA-DR10-expressing
100 Comparative
pharmacokinetic studies in mice with Raji B-cell lymphom
101 Employing oral
pharmacokinetic studies in mice, comparing drug levels i
102 e model of cellular permeability and in vivo
pharmacokinetic studies in mice, thereby representing ad
103 d-type Fc have been isolated and analyzed in
pharmacokinetic studies in mice.
104 Pharmacokinetic studies in normal and tumor-bearing rats
105 msstrahlung is less suitable for imaging and
pharmacokinetic studies in patients.
106 Pharmacokinetic studies in PC-3 xenograft SCID mice show
107 d showcase the racemization of the scaffold,
pharmacokinetic studies in preclinical species, and the
108 In vivo
pharmacokinetic studies in rabbit tear fluid showed sign
109 Pharmacokinetic studies in rats demonstrated 3.3-fold hi
110 Pharmacokinetic studies in rats demonstrated that the pr
111 Pharmacokinetic studies in rats showed that 26 h was ora
112 Oral
pharmacokinetic studies in rats showed that ASD curcumin
113 Pharmacokinetic studies in rats showed that compound 32
114 Finally, in validation and
pharmacokinetic studies in rats, SOD outperformed other
115 Results from
pharmacokinetic studies in rhesus monkeys demonstrated t
116 a useful tool to avoid unnecessary dedicated
pharmacokinetic studies in the adolescent population dur
117 physicochemical, in vitro ADME, and in vivo
pharmacokinetic studies in the rat and the dog.
118 Pharmacokinetic studies in the rat indicate that, in con
119 Pharmacokinetic studies in the rat indicated that this c
120 Pharmacokinetic studies in the rat show 20 to be 42% ora
121 ated relatively low clearance in intravenous
pharmacokinetic studies in three species, and it is the
122 Following initial
pharmacokinetic studies in two pigs to determine desirab
123 Pharmacokinetic studies in vivo demonstrated that midazo
124 In addition,
pharmacokinetic studies in VWF knockout mice indicated t
125 essments regarding the need for an intensive
pharmacokinetic study in adolescents have been performed
126 A
pharmacokinetic study in experiment 2 showed that MH6-va
127 A
pharmacokinetic study in mice showed that GSK2801 had re
128 he promising dibenzoxepinone inhibitor 3i, a
pharmacokinetic study in mice was conducted.
129 n was further characterized in a single-dose
pharmacokinetic study in rat (t1/2 = 3.7 h; F = 86%) and
130 This method was successfully applied to the
pharmacokinetic study in rats for detection of GLB after
131 n following subcutaneous administration in a
pharmacokinetic study in rats.
132 plasma/tissues, and then examined in a full
pharmacokinetic study in rats.
133 Pharmacokinetics studies in rats showed that 16g was ora
134 ith human MDR1 gene (MDCK/MDR1), followed by
pharmacokinetics studies in rats.
135 A
pharmacokinetics study in rhesus monkeys of one of the I
136 asses of pharmacokinetics abstracts: in vivo
pharmacokinetics studies,
in vivo pharmacogenetic studie
137 Pharmacokinetic studies indicate high initial influx of
138 Current
pharmacokinetic studies indicate that approximately half
139 Pharmacokinetic studies indicate that cyclophosphamide a
140 oses of rhuMAb VEGF were well tolerated, and
pharmacokinetic studies indicate that doses of > or = 0.
141 Tissue distribution and
pharmacokinetic studies indicated intestinal CFTR(inh)-1
142 Pharmacokinetic studies indicated that 3-CP in tumors wa
143 Pharmacokinetic studies indicated that capecitabine and
144 Pharmacokinetic studies indicated that compound 19 displ
145 Pharmacokinetic studies indicated that low oral bioavail
146 Pharmacokinetic studies indicated that the amount of sys
147 Pharmacokinetic studies investigated the tissue distribu
148 n the accuracy of LC/MS measurements used in
pharmacokinetic studies is examined.
149 On the day of the
pharmacokinetic study,
minimum Concentration (Cmin), 12-
150 Neither in single-dose
pharmacokinetic studies nor the transplant recipients we
151 Pharmacokinetic studies obtained in 27 patients at eight
152 Population
pharmacokinetic studies of 58 patients demonstrated that
153 Pharmacokinetic studies of BBI have been performed in an
154 Pharmacokinetic studies of carboplatin were performed fo
155 In addition,
pharmacokinetic studies of CPT-11 and SN-38 in these ani
156 to progression, median survival, safety, and
pharmacokinetic studies of gemcitabine.
157 Pharmacokinetic studies of irofulven revealed dose-propo
158 zamines is also presented in addition to the
pharmacokinetic studies of manzamine A (5).
159 Oral and intravenous
pharmacokinetic studies of manzamine A in rats indicated
160 Pharmacokinetic studies of N-myristoylalendronic acid re
161 Pharmacokinetic studies of paclitaxel were also performe
162 The applicability of the methodology to
pharmacokinetic studies of PEITC in humans is demonstrat
163 The objective was to perform safety and
pharmacokinetic studies of purified unconjugated isoflav
164 Plasma
pharmacokinetic studies of single-dose NSC23925b alone o
165 Pharmacokinetic studies of TFPI(C127 )in vivo demonstrat
166 In vivo
pharmacokinetic studies of the (111)In-DOTA-8-Aoc-BBN[7-
167 The
pharmacokinetic studies of the optimized formulation wer
168 Pharmacokinetic studies of U-50488 in plasma and brain w
169 Pharmacokinetic studies of vesnarinone revealed signific
170 The method was applied to the
pharmacokinetic study of a mAb dosed in cynomolgus monke
171 A comparative
pharmacokinetic study of a nanoscale micellar docetaxel
172 A
pharmacokinetic study of an oral formulation (10 mg imme
173 The
pharmacokinetic study of DMA at oral and intravenous dos
174 We performed a
pharmacokinetic study of IP CsA followed by a phase I do
175 A phase I and
pharmacokinetic study of IT mafosfamide was performed to
176 We conducted a 2-sample
pharmacokinetic study of oseltamivir in 12 premature inf
177 We report results of a phase I trial and
pharmacokinetic study of pemetrexed (LY231514) in childr
178 Thus, we conducted a single-dose
pharmacokinetic study of TFV gel applied 1 or 24 hours b
179 We performed a phase I and
pharmacokinetic study of thalidomide with carboplatin in
180 We conducted a phase I and
pharmacokinetic study of the epidermal growth factor rec
181 A dose-escalation phase I and
pharmacokinetic study of the farnesyltransferase inhibit
182 A
pharmacokinetic study of the new HM administration metho
183 In the ILLUMENATE PK study (
Pharmacokinetic Study of the Stellarex Drug-Coated Angio
184 his LC-MS approach was also applied to a rat
pharmacokinetic study of the therapeutic monoclonal anti
185 On the basis of a previous
pharmacokinetic study of the use of intravenous ganciclo
186 Therefore, we initiated a phase I
pharmacokinetic study of this combination in our gastric
187 In vivo
pharmacokinetics studies of 7ii showed high liver distri
188 A
pharmacokinetics study of two mutant IgG2 antibodies wit
189 METHODS AND Published
pharmacokinetic studies on piperaquine were identified t
190 Pharmacokinetic studies on these agents in the mouse rev
191 In the
pharmacokinetic study,
OROS-methylphenidate treatment pr
192 lanar and SPECT/CT imaging was performed and
pharmacokinetics studied over 2-3 d.
193 In vivo biodistribution and
pharmacokinetic studies performed using SKH1 hairless mi
194 The purpose of this
pharmacokinetic study performed in stable renal transpla
195 e LC-HRMS was then successfully applied to a
pharmacokinetic study performed on male Sprague-Dawley r
196 Two
pharmacokinetic studies (
PK1, PK2) were performed 10 day
197 Pharmacokinetic studies revealed bioavailabilities of 2%
198 n 10(-9), a clinically acceptable level, and
pharmacokinetic studies revealed in vivo exposure levels
199 Pharmacokinetic studies revealed that 1294 is well absor
200 Pharmacokinetic studies revealed that 230 appears rapidl
201 The
pharmacokinetic studies revealed that about three times
202 Pharmacokinetic studies revealed that compound 57 had a
203 Our
pharmacokinetic studies revealed that intravenously admi
204 Pharmacokinetic studies revealed that it had a moderate
205 Pharmacokinetic study revealed that DC nanozymes signifi
206 ated by in vivo imaging technique and ocular
pharmacokinetics studies revealing that the clearance of
207 Pharmacokinetic studies should be carried out to evaluat
208 The in vivo
pharmacokinetic studies showed a high level of receptor-
209 Pharmacokinetic studies showed a quick absorption of 2 i
210 Pharmacokinetic studies showed cyclosporin in the form o
211 Pharmacokinetic studies showed dose-independent clearanc
212 Pharmacokinetic studies showed pentostatin significantly
213 Pharmacokinetic studies showed rapid clearance of circul
214 Pharmacokinetic studies showed rapid gastrointestinal ab
215 Metabolism and
pharmacokinetic studies showed that 21 exhibited a plasm
216 Pharmacokinetic studies showed that 64Cu-TETA-OC was rap
217 Pharmacokinetic studies showed that administration of pa
218 Pharmacokinetic studies showed that anti-HER2/neu IgG3-(
219 Pharmacokinetic studies showed that more than 50% of mon
220 tratracheally, and the blood cells from such
pharmacokinetic study showed good receptor occupancy of
221 Pharmacokinetics studies showed a significant increase o
222 Pharmacokinetics study showed that high Mw mP-PTX was cl
223 on efficiency was further confirmed from the
pharmacokinetic studies since the nanoporous mannitol ex
224 These results along with
pharmacokinetic studies suggest that 6j could be a promi
225 Pharmacokinetic studies suggest that lack of GSTM1 enzym
226 Pharmacokinetic studies suggested a long terminal half-l
227 Cellular and plasma
pharmacokinetic studies suggested dose proportionality b
228 Pharmacokinetic studies suggested that porcine skin derm
229 Instead,
pharmacokinetic studies suggested that the differences i
230 Previous
pharmacokinetic studies suggested that the unfavorable b
231 The present
pharmacokinetic study supports further trials to determi
232 acy data obtained during a previous phase II
pharmacokinetic study that compared combined ABZ plus PZ
233 In the short-term
pharmacokinetic studies,
the cornea had CsA concentratio
234 In the
pharmacokinetics studies,
the SND formulation increased
235 In a
pharmacokinetics study,
the blood concentrations of the
236 They exhibit moderate oral exposure in rat
pharmacokinetic studies to achieve sufficient multiples
237 imaging examinations were supplemented with
pharmacokinetic studies to enable further assessment of
238 ildren should be developed early and used in
pharmacokinetic studies to guide dose selection.
239 We conducted a
pharmacokinetic study to evaluate EFV trough concentrati
240 Participants received rFIX for
pharmacokinetic studies,
treatment of or prophylaxis aga
241 In phase I
pharmacokinetic studies,
UFT given orally on a 28-day sc
242 Pharmacokinetic studies using gnotobiotic mice revealed
243 Ocular
pharmacokinetic studies using MRI are noninvasive and pr
244 Moreover,
pharmacokinetic study using 2-in-1 micelles indicated th
245 luidic blood-counting system for preclinical
pharmacokinetic studies was developed.
246 The highest tumor uptake in
pharmacokinetic studies was obtained with LLP2A-DOTA and
247 A
pharmacokinetic study was performed in 12 HIV-negative m
248 A prospective
pharmacokinetic study was performed in 12 recipients of
249 A
pharmacokinetic study was performed to determine the L d
250 99m radiolabeled human serum albumin, and a
pharmacokinetic study was performed.
251 Using a crossover design, a 12-hr
pharmacokinetic study was then conducted.
252 d), two-sequence, crossover and steady-state
pharmacokinetic study was undertaken to compare twice-da
253 -week, randomized, double-blind, multicenter
pharmacokinetics study was conducted to compare the clin
254 the applicability of the LC-MS/MS method for
pharmacokinetic studies,
we quantified rhTRAIL(WT) and r
255 Pharmacokinetic studies were also performed.
256 Pharmacokinetic studies were available for 79 patients.
257 Pharmacokinetic studies were carried out in 23 patients
258 In vivo
pharmacokinetic studies were carried out on hairless rat
259 Pharmacokinetic studies were conducted on day 1 to attai
260 Parallel plasma and cellular
pharmacokinetic studies were conducted.
261 Pharmacokinetic studies were done in wild-type and OATP1
262 mens for children required codification, and
pharmacokinetic studies were encouraged to develop optim
263 Pharmacokinetic studies were fitted to a linear, 2-compa
264 Additionally, in vivo
pharmacokinetic studies were implemented and the PRP's a
265 Pharmacokinetic studies were obtained during chloramphen
266 Pharmacokinetic studies were obtained for all patients.
267 Serial samples of CSF for
pharmacokinetic studies were obtained in a subset of pat
268 Serial samples of CSF for
pharmacokinetic studies were obtained in a subset of pat
269 Pharmacokinetic studies were performed by measuring radi
270 Pharmacokinetic studies were performed during course one
271 Pharmacokinetic studies were performed during cycle 1 fo
272 Pharmacokinetic studies were performed during the first
273 Pharmacokinetic studies were performed during the first
274 liter] x minutes) among patient cohorts, and
pharmacokinetic studies were performed for comparison.
275 Five phase 1, multiple-dose, open-label
pharmacokinetic studies were performed in 144 healthy vo
276 Feasibility and
pharmacokinetic studies were performed in nonhuman prima
277 To begin defining underlying mechanisms,
pharmacokinetic studies were performed in P28 rats; bFGF
278 The
pharmacokinetic studies were performed in Sprague-Dawley
279 Pharmacokinetic studies were performed on days 1 and 5 o
280 Pharmacokinetic studies were performed on days 1 and 5 t
281 In vitro metabolism and initial
pharmacokinetic studies were performed on selected compo
282 Pharmacokinetic studies were performed to characterize t
283 Biodistribution and
pharmacokinetic studies were performed to determine the
284 Pharmacokinetic studies were performed with the initial
285 Pharmacokinetic studies were performed with the initial
286 blind, placebo-controlled safety, tolerance,
pharmacokinetic studies were undertaken in a total of 12
287 Serial blood samples for thalidomide
pharmacokinetics studies were obtained after the first d
288 ecan exposure was achieved in seven of eight
pharmacokinetic studies when the topotecan plasma AUC wa
289 Rat
pharmacokinetic studies with compound 17 demonstrate low
290 Pharmacokinetic studies with native, desialylated, and d
291 Moreover, preliminary
pharmacokinetic studies with NM-324 are being conducted
292 Pharmacokinetic studies with RO-9187 in rats and dogs sh
293 Pharmacokinetic studies with the Mdr1a P-gp substrates l
294 In vivo pharmacodynamic and
pharmacokinetic studies with two examples, 12e and 12j,
295 d was applied successfully on the underlying
pharmacokinetic study with enhanced sample preparation t